{"id":297251,"date":"2019-10-09T20:00:28","date_gmt":"2019-10-10T03:00:28","guid":{"rendered":"https:\/\/nai500.com\/blog\/2019\/10\/chi-med-starts-syk-inhibitor\/"},"modified":"2019-10-09T20:02:23","modified_gmt":"2019-10-10T03:02:23","slug":"%e5%92%8c%e8%a8%98%e4%b8%ad%e5%9c%8b%e9%86%ab%e7%99%82%e7%a7%91%e6%8a%80%e9%80%b2%e8%a1%8csyk%e6%8a%91%e5%88%b6%e5%8a%91%e7%9a%84%e5%85%a8%e7%90%83%e8%a9%a6%e9%a9%97","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hant\/blog\/2019\/10\/%e5%92%8c%e8%a8%98%e4%b8%ad%e5%9c%8b%e9%86%ab%e7%99%82%e7%a7%91%e6%8a%80%e9%80%b2%e8%a1%8csyk%e6%8a%91%e5%88%b6%e5%8a%91%e7%9a%84%e5%85%a8%e7%90%83%e8%a9%a6%e9%a9%97\/","title":{"rendered":"\u548c\u8a18\u4e2d\u570b\u91ab\u7642\u79d1\u6280\u9032\u884cSyk\u6291\u5236\u5291\u7684\u5168\u7403\u8a66\u9a57"},"content":{"rendered":"<p>\u548c\u8a18\u4e2d\u570b\u91ab\u7642\u79d1\u6280\u5df2\u958b\u59cb\u5c0d\u5176\u65b0\u578b\u5c0f\u5206\u5b50Syk\u6291\u5236\u5291\u5728\u5fa9\u767c\u6216\u96e3\u6cbb\u6027\u6dcb\u5df4\u7624\u60a3\u8005\u4e2d\u9032\u884c\u5168\u7403I \/ Ib\u671f\u7814\u7a76\u3002\u8a72\u8a66\u9a57\u7684\u4e3b\u8981\u7d42\u9ede\u662f\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\uff0c\u76e1\u7ba1\u9084\u5c07\u76e3\u6e2cPK\u548c\u5ba2\u89c0\u7de9\u89e3\u7387\u3002 \u548c\u8a18\u4e2d\u570b\u91ab\u7642\u79d1\u6280\u671f\u671b\uff0c\u7b2c\u4e8c\u4ee3Syk\u6291\u5236\u5291HMPL-523\u8207\u7b2c\u4e00\u4ee3\u5019\u9078\u85e5\u7269\u76f8\u6bd4\uff0c\u5f15\u8d77\u7684\u5b89\u5168\u6027\u554f\u984c\u66f4\u5c11\u3002\u5728\u8f03\u65e9\u7684\u6fb3\u5927\u5229\u4e9e\u8a66\u9a57\u4e2d\uff0cHMPL-523\u986f\u793a\u4e86\u53ef\u63a5\u53d7\u7684\u5b89\u5168\u6027\u3002\u8a72\u5019\u9078\u85e5\u7269\u9084\u5728\u4e00\u9805\u4e2d\u570b\u514d\u75ab\u6027\u8840\u5c0f\u677f\u6e1b\u5c11\u7665\u60a3\u8005\u7684I\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u63a5\u53d7\u6e2c\u8a66\u3002<br \/>\n\u82f1\u6587\u4f86\u6e90\uff1aChina Biotoday<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hutchison China MediTech (Chi-Med) has started a global Phase I\/Ib study of its novel small molecule Syk inhibitor in patients with relapsed or refractory lymphoma. The primary endpoints of the trial are safety and tolerability, though PK and objective response rates will also be monitored. <\/p>\n","protected":false},"author":9,"featured_media":270776,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[426],"tags":[563,644,564],"class_list":["post-297251","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hant","tag--zh-hant","tag-644","tag-564","sectors-life-science-zh-hant","locations-china-zh-hant","exchange-609"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/297251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=297251"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/297251\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media\/270776"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=297251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=297251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=297251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}